Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, van der Veen F, van Wely M. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23:560–79. https://doi.org/10.1093/humupd/dmx017.

Article  CAS  PubMed  Google Scholar 

Copperman AB, Benadiva C. Optimal usage of the GnRH antagonists: a review of the literature. Reproductive Biology and Endocrinology. 2013;11:20. https://doi.org/10.1186/1477-7827-11-20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750. https://doi.org/10.1002/14651858.CD001750.pub4.

Article  PubMed  Google Scholar 

Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;CD008046. https://doi.org/10.1002/14651858.CD008046.pub4.

Arce JC, Andersen AN, Fernandez-Sanchez M, Visnova H, Bosch E, Garcia-Velasco JA, Barri P, de Sutter P, Klein BM, Fauser BC. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2014;102:1633–1640e1635. https://doi.org/10.1016/j.fertnstert.2014.08.013.

Article  CAS  PubMed  Google Scholar 

Arce J-C, Klein B, Erichsen L. Using AMH for determining a stratified gonadotropin dosing regimen for IVF/ICSI and optimizing outcomes. In: Anti-Müllerian Hormone: biology, role in ovarian function and clinical significance Edited by Seifer D, Tal R. Hauppauge: Nova Science Publishers, Inc; 2016: pp 83–102.

Nyboe Andersen A, Nelson SM, Fauser BC, Garcia-Velasco JA, Klein BM, Arce JC. Group E-s: individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107:387–396e384. https://doi.org/10.1016/j.fertnstert.2016.10.033.

Article  CAS  PubMed  Google Scholar 

Ishihara O, Arce JC. Japanese Follitropin Delta Phase 3 Trial G: individualized follitropin delta dosing reduces OHSS risk in japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021;42:909–18. https://doi.org/10.1016/j.rbmo.2021.01.023.

Article  CAS  PubMed  Google Scholar 

Qiao J, Zhang Y, Liang X, Ho T, Huang HY, Kim SH, Goethberg M, Mannaerts B, Arce JC. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in asian IVF/ICSI patients. Hum Reprod. 2021;36:2452–62. https://doi.org/10.1093/humrep/deab155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fernandez-Sanchez M, Visnova H, Yuzpe A, Klein BM, Mannaerts B, Arce JC, Esther, Group E-S. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reprod Biomed Online. 2019;38:528–37. https://doi.org/10.1016/j.rbmo.2018.12.032.

Article  CAS  PubMed  Google Scholar 

Tremellen KP, Lane M. Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. Hum Reprod. 2010;25:1219–24. https://doi.org/10.1093/humrep/deq059.

Article  CAS  PubMed  Google Scholar 

Toftager M, Bogstad J, Bryndorf T, Lossl K, Roskaer J, Holland T, Praetorius L, Zedeler A, Nilas L, Pinborg A. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod. 2016;31:1253–64. https://doi.org/10.1093/humrep/dew051.

Article  CAS  PubMed  Google Scholar 

Fernández Sánchez M, Višnova H, Larsson P, Yding Andersen C, Filicori M, Blockeel C, Pinborg A, Khalaf Y, Mannaerts B, Rainbow Study Group. A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol. Hum Reprod. 2022;37:1161–74. https://doi.org/10.1093/humrep/deac061.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alpha Scientists in Reproductive M, Embryology ESIGo: The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011, 26:1270–1283. https://doi.org/10.1093/humrep/der037.

Gardner D, Schoolcraft W. In vitro culture of human blastocysts. In: Towards reproductive certainty The plenary proceedings of the 11th world congress on in vitro fertilization and human reproductive genetics Edited by Jansen R, Mortimer D: The Parthenon Publishing Group; 1999: pp 378–388.

Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–40. https://doi.org/10.1097/00006254-198906000-00004.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency guideline EMEA/CHMP/313666/. 2005. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data. May 2006. Available from: https://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf. Accessed 20 July, 2022

Havelock J, Aaris Henningsen AK, Mannaerts B, Arce JC, Esther, Groups E-T. Pregnancy and neonatal outcomes in fresh and frozen cycles using blastocysts derived from ovarian stimulation with follitropin delta. J Assist Reprod Genet. 2021;38:2651–61. https://doi.org/10.1007/s10815-021-02271-5.

Article  PubMed  PubMed Central  Google Scholar 

Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27:170–207. https://doi.org/10.1210/er.2005-0015.

Article  PubMed  Google Scholar 

Fatemi H, Bilger W, Denis D, Griesinger G, La Marca A, Longobardi S, Mahony M, Yin X, D’Hooghe T. Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007–2017). Reprod Biol Endocrinol. 2021;19:68. https://doi.org/10.1186/s12958-021-00744-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod. 1993;8:369–73. https://doi.org/10.1093/oxfordjournals.humrep.a138053.

Article  PubMed  Google Scholar 

Khalaf Y, El-Toukhy T, Taylor A, Braude P. Increasing the gonadotrophin dose in the course of an in vitro fertilization cycle does not rectify an initial poor response. Eur J Obstet Gynecol Reprod Biol. 2002;103:146–9. https://doi.org/10.1016/s0301-2115(02)00036-2.

Article  CAS  PubMed  Google Scholar 

Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73:1155–8. https://doi.org/10.1016/s0015-0282(00)00518-5.

Article  CAS  PubMed  Google Scholar 

Wirleitner B, Schuff M, Stecher A, Murtinger M, Vanderzwalmen P. Pregnancy and birth outcomes following fresh or vitrified embryo transfer according to blastocyst morphology and expansion stage, and culturing strategy for delayed development. Hum Reprod. 2016;31:1685–95. https://doi.org/10.1093/humrep/dew127.

Article  CAS  PubMed  Google Scholar 

Qiao J, Lu G, Zhang HW, Chen H, Ma C, Olofsson JI, Witjes H, Heijnen E, Mannaerts B. A randomized controlled trial of the GnRH antagonist ganirelix in chinese normal responders: high efficacy and pregnancy rates. Gynecol Endocrinol. 2012;28:800–4. https://doi.org/10.3109/09513590.2012.665103.

Article  CAS  PubMed  Google Scholar 

Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, Muasher SJ. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril. 2014;101:967–73. https://doi.org/10.1016/j.fertnstert.2013.12.026.

Article  PubMed  Google Scholar 

Magnusson A, Kallen K, Thurin-Kjellberg A, Bergh C. The number of oocytes retrieved during IVF: a balance between efficacy and safety. Hum Reprod. 2018;33:58–64. https://doi.org/10.1093/humrep/dex334.

Article  PubMed  Google Scholar 

Višnová H, Papaleo E, Martin FS, Koziol K, Klein BM, Mannaerts B. Clinical outcomes of potential high responders after individualized FSH dosing based on anti-mullerian hormone and body weight. Reprod Biomed Online. 2021;43:1019–26. https://doi.org/10.1016/j.rbmo.2021.08.024.

Article  CAS  PubMed  Google Scholar